Hints and tips:
Related Special Reports
...Curaleaf is listed on the Toronto Stock Exchange in Canada, which legalised consumption and limited production of cannabis in 2018....
...“Having a broken leg didn’t make me a lesser person, but it did dictate my immediate actions and greatly limited my options in the moment,” the 57-year-old said on Tuesday....
...In the UK companies cannot advertise prescription medicines to the public but are allowed to promote them to healthcare professionals....
...In recommending that investors oppose the plans, ISS said it acknowledged that AstraZeneca, the UK’s second-largest public company by market value, has “a global reach, is in a high-paying sector, with a...
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...If treatment facilities are unavailable or unaffordable, the diagnosis may be of limited benefit — and may add to the psychological burden on patients....
...It already made its diagnostics products in the country but had “limited manufacturing for pharma”, he added....
...The Feds said that the executive held material non-public information about Incyte — that it would benefit from merger speculation — which he had a duty not to trade on....
...Doctors must listen to women; the public and private sector have to collaborate for better-tailored research and clinical trials....
...The company said the decision was partly driven by huge demand for weight-loss drugs....
...to public markets in 2001....
...Last year, at the height of pricing negotiations, leaders from 16 of the world’s largest generic and biosimilar companies wrote asking for clarity on specific aspects of the deal....
...A total of nine biotechs have gone public on US markets this quarter, raising $1.4bn between them....
...This would involve pharmaceutical companies helping to fund the monitoring of new pathogens, which would in turn speed efforts at vaccine development....
...In the UK, Wegovy is available in limited supply on the NHS but patients using private healthcare can pay up to £300 for a month’s supply. Costs are similar in Denmark and Germany....
...The Association of the British Pharmaceutical Industry, the drugmakers’ trade body, said it supported “this tough deal” even though the agreement would continue to restrict pharmaceutical companies’ sales...
...make up the backbone of pharmaceutical care....
...“So it is particularly important to protect our limited [stock] of effective anti-fungal drugs.”...
...“The public debate about Bayer’s future was too narrowly focused on a break-up,” he said, adding that Anderson was right to address Bayer’s underlying problems....
...This is not to play off global public health against climate policy. We cannot pick our challenges....
...Last year, a number of UK companies, including veterinary pharmaceuticals company Dechra and the restaurant group behind Japanese dining chain Wagamama, were acquired by buyout firms....
...Supply shortages are not limited to the UK....
...It will allow shareholders in participating companies to sell their stock on a limited number of days each year....
...In contrast, pharmaceutical companies raised just $160mn for antibiotic research, a decline over the decade. Commercial activity and research in antibiotics have been in decline since the 1980s....
...They mooted that the £15bn of top-ranking bonds could face losses of 5-10 per cent in the event that the utility has to come back under public control....
International Edition